Biogen

NASDAQ: BIIB ↗ $196.58 USD ~$30B MCAP

#Multiple Sclerosis #Spinal Muscular Atrophy (SMA)#Alzheimer's Disease #Rare Neurological Diseases #Friedreich's Ataxia #Neuroscience

Biogen is a leading global biotechnology company that discovers, develops, and delivers innovative therapies for serious neurological and neurodegenerative diseases. Its portfolio includes medicines for multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, and rare diseases, with a growing late-stage neurology pipeline and recent expansion into rare diseases through the Reata Pharmaceuticals acquisition.

Company Info

Sector: Biotechnology / Neuroscience

Headquarters: Cambridge, Massachusetts, USA

Founded: 1978

Website: www.biogen.com/

Upcoming Milestones & Key Dates

Q2 2026

Earnings

Q1 2026 Earnings — Reata integration and Leqembi commercial update

2026

Conference

Pipeline updates at R&D Day, including next-gen antisense programs

Clinical Development Pipeline

Leqembi (lecanemab)

Target: Anti-amyloid beta protofibril antibody (with Eisai)

Early Alzheimer's disease (mild cognitive impairment / mild dementia)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Skyclarys (omaveloxolone)

Target: Nrf2 activator (mitochondrial function)

Friedreich's ataxia

Preclinical

Phase 1

Phase 2

Phase 3

Approved

BIIB080

Target: Tau-targeting antisense oligonucleotide (ASO)

Alzheimer's disease and progressive supranuclear palsy

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Christopher A. Viehbacher

President and Chief Executive Officer

Michael McDonnell

Executive Vice President, Chief Financial Officer

Dr. Priya Singhal, M.D., M.P.H.

Executive Vice President, Head of Development and Chief Medical Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →